Discordant results between 582 paired molecular tests with interpretable results performed for assessment of rifampicin-resistant TB at routine laboratories in South Africa
| Test and results . | Sample pairsa . | Proportion (95% CI) . |
|---|---|---|
| Xpert and MTBDRplus (n=297) | ||
| concordant RIFR | 254 | 85.5% (81.1%–89.1%) |
| concordant RIFS | 0 | 0% |
| Xpert RIFS MTBDRplus RIFR | 1 | 0.4% (0.06%–1.9%) |
| Xpert RIFR MTBDRplus RIFS | 42 | 14.1% (10.6%–18.6%) |
| Repeat Xpert (n=72) | ||
| concordant RIFR | 68 | 94.4% (86.6%–97.8%) |
| concordant RIFS | 0 | 0% |
| discordant | 4 | 5.6% (2.2%–13.4%) |
| Repeat MTBDRplus (n=213) | ||
| concordant RIFR | 194 | 91.1% (86.5%–94.2%) |
| concordant RIFS | 10 | 4.7% (2.6%–8.4%) |
| discordant | 9 | 4.2% (2.2%–7.8%) |
| Test and results . | Sample pairsa . | Proportion (95% CI) . |
|---|---|---|
| Xpert and MTBDRplus (n=297) | ||
| concordant RIFR | 254 | 85.5% (81.1%–89.1%) |
| concordant RIFS | 0 | 0% |
| Xpert RIFS MTBDRplus RIFR | 1 | 0.4% (0.06%–1.9%) |
| Xpert RIFR MTBDRplus RIFS | 42 | 14.1% (10.6%–18.6%) |
| Repeat Xpert (n=72) | ||
| concordant RIFR | 68 | 94.4% (86.6%–97.8%) |
| concordant RIFS | 0 | 0% |
| discordant | 4 | 5.6% (2.2%–13.4%) |
| Repeat MTBDRplus (n=213) | ||
| concordant RIFR | 194 | 91.1% (86.5%–94.2%) |
| concordant RIFS | 10 | 4.7% (2.6%–8.4%) |
| discordant | 9 | 4.2% (2.2%–7.8%) |
RIFR, rifampicin resistant; RIFS, rifampicin susceptible.
Samples included in the sample pairs were collected on different dates. The number of sample pairs included in the Xpert versus MTBDRplus, repeat Xpert and repeat MTBDRplus analyses differed, depending on which tests were requested by the clinician in charge of patient care.
Discordant results between 582 paired molecular tests with interpretable results performed for assessment of rifampicin-resistant TB at routine laboratories in South Africa
| Test and results . | Sample pairsa . | Proportion (95% CI) . |
|---|---|---|
| Xpert and MTBDRplus (n=297) | ||
| concordant RIFR | 254 | 85.5% (81.1%–89.1%) |
| concordant RIFS | 0 | 0% |
| Xpert RIFS MTBDRplus RIFR | 1 | 0.4% (0.06%–1.9%) |
| Xpert RIFR MTBDRplus RIFS | 42 | 14.1% (10.6%–18.6%) |
| Repeat Xpert (n=72) | ||
| concordant RIFR | 68 | 94.4% (86.6%–97.8%) |
| concordant RIFS | 0 | 0% |
| discordant | 4 | 5.6% (2.2%–13.4%) |
| Repeat MTBDRplus (n=213) | ||
| concordant RIFR | 194 | 91.1% (86.5%–94.2%) |
| concordant RIFS | 10 | 4.7% (2.6%–8.4%) |
| discordant | 9 | 4.2% (2.2%–7.8%) |
| Test and results . | Sample pairsa . | Proportion (95% CI) . |
|---|---|---|
| Xpert and MTBDRplus (n=297) | ||
| concordant RIFR | 254 | 85.5% (81.1%–89.1%) |
| concordant RIFS | 0 | 0% |
| Xpert RIFS MTBDRplus RIFR | 1 | 0.4% (0.06%–1.9%) |
| Xpert RIFR MTBDRplus RIFS | 42 | 14.1% (10.6%–18.6%) |
| Repeat Xpert (n=72) | ||
| concordant RIFR | 68 | 94.4% (86.6%–97.8%) |
| concordant RIFS | 0 | 0% |
| discordant | 4 | 5.6% (2.2%–13.4%) |
| Repeat MTBDRplus (n=213) | ||
| concordant RIFR | 194 | 91.1% (86.5%–94.2%) |
| concordant RIFS | 10 | 4.7% (2.6%–8.4%) |
| discordant | 9 | 4.2% (2.2%–7.8%) |
RIFR, rifampicin resistant; RIFS, rifampicin susceptible.
Samples included in the sample pairs were collected on different dates. The number of sample pairs included in the Xpert versus MTBDRplus, repeat Xpert and repeat MTBDRplus analyses differed, depending on which tests were requested by the clinician in charge of patient care.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
